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Abstract
Background: Luteinising hormone-releasing hormone agonists ([21_TD$DIFF]LHRHa), used as andro-
gen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum
oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transder-
mal oestradiol is a potential alternative to LHRHa.
Objective: To compare BMD change inmen receiving either LHRHa or oestradiol patches
( [22_TD$DIFF]OP).
Design, setting, and participants: Men with locally advanced or metastatic PCa partici-
pating in the randomised UK Prostate Adenocarcinoma [23_TD$DIFF] ransCutaneous Hormones
(PATCH) trial (allocation ratio of 1:2 for [11_TD$DIFF]LHRHa:OP, 2006–2011; 1:1, thereafter) were
recruited into a BMD study (2006–2012). Dual-energy x-ray absorptiometry scans were
performed at baseline, 1 yr, and 2 yr.
Interventions: LHRHa as per local practice, OP (FemSeven 100 [2_TD$DIFF]mg/24 [2_TD$DIFF]h patches).
Outcomemeasurements and statistical analysis: The primary outcomewas 1-yr change
in lumbar spine (LS) BMD from baseline compared between randomised arms using
analysis of covariance.
Results and limitations: A total of 74 eligible men (LHRHa 28, OP 46) participated from
seven centres. Baseline clinical characteristics and 3-mo castration rates (testosterone
1.7 nmol/l, LHRHa 96% [26 of 27], OP 96% [43 of 45]) were similar between arms. Mean
1-yr change in LS BMD was 0.021 g/cm3 [20_TD$DIFF] for patients randomised to the LHRHa arm
(mean percentage change 1.4%) and +0.069 g/cm3 for the OP arm (+6.0%; p < 0.001).
Similar patterns were seen in hip and total body measurements. The largest difference
between arms was at 2 yr for those remaining on allocated treatment only: LS BMD
mean percentage change LHRHa 3.0% and OP +7.9% (p < 0.001).
Conclusions: Transdermal oestradiol as a single agent produces castration levels of
testosterone while mitigating BMD loss. These early data provide further supporting
oinevidence for the ong* Corresponding author. Me
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Men with locally advanced or metastatic prostate cancer 
and long-term hormone therapy planned
Randomisation
Stage 2: Preplanned interim eﬃcacy analysis (n = 638; June 2013)
Primary outcome measure: PFS
Stage 1: Cardiovascular safety (n = 254; completed April 2010)
Primary outcome measure: cardiovascular morbidity and mortality
Transdermal      
oestradiol patches
LHRH agonists 
(control)
Final phase 3 eﬃcacy evaluaon (overall target n = 2150; expected 
compleon date about 2021)
Coprimary outcome measures: overall survival and PFS
Fig. 1 – PATCH trial schema. The allocation ratio was 1:2 [9_TD$DIFF] for luteinising
hormone-releasing hormone [10_TD$DIFF] agonists ( [11_TD$DIFF]LHRHa)[1_TD$DIFF] to oestradiol [12_TD$DIFF]patches
during the first stage of the trial (before February 21, 2011) to optimise
the experience of the patches and 1:1 thereafter. Patients in the bone
mineral density study were enrolled from seven of the participating
sites between August 2006 and September 2012.
PFS = progression-free survival.
Patient summary: This study found that prostate cancer patients treated with transder-
mal oestradiol for hormonal therapy did not experience the loss in bone mineral density
seen with luteinising hormone-releasing hormone agonists. Other clinical outcomes for
this treatment approach are being evaluated in the ongoing PATCH trial.
Trial registration: ISRCTN70406718, PATCH trial (ClinicalTrials.gov NCT00303784).
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Androgen deprivation therapy (ADT), widely used in the
management of prostate cancer (PCa), is usually achieved in
contemporary practice through the administration of
luteinising hormone-releasing hormone agonists (LHRHa)
or antagonists. More than half of the men diagnosed with
PCa are expected to be treated with ADT at some point
during the course of their disease, many for a decade or
longer [1]. LHRHa [24_TD$DIFF]suppress testosterone to castration levels
but also [25_TD$DIFF]deplete oestradiol because approximately 80% of
oestradiol in men is derived by aromatisation from
testosterone [2]. The effect of oestradiol deficiency on bone
health in women is well established, but only in the last 10–
15 yr has the negative impact of LHRHa on bone health in
men with PCa been documented [3–6].
Average declines in bone mineral density (BMD) of
between 2% and 10% per year were reported in studies of
men treated with LHRHa [3–5,7,8], resulting in an increased
incidence of fractures with associated morbidity and
mortality [9,10]. The rate of fracture increases with the
duration of LHRHa use aswell as inmenwith a high baseline
risk of skeletal complications [9,10], with important
implications for PCa patients who are often elderly and
have other comorbidities.
Parenteral oestradiol is a potential alternative to LHRHa
in the management of PCa. Administering oestradiol
suppresses androgen production through a negative feed-
back loop involving the hypothalamic-pituitary axis [11]
and avoids the fall in endogenous oestradiol associatedwith
castration levels of testosterone. Oral oestrogen (eg,
diethylstilboestrol [DES]) was previously used for ADT
before the development of LHRHa but was discontinued as
first-line treatment because of the mainly embolic cardio-
vascular (CVS) toxicity [12] that was attributed to first-pass
hepatic metabolism [13]. Administration of oestradiol
parenterally (eg, intravenous, intramuscular, or transder-
mal) avoids first-pass hepatic metabolism [14], so it should
mitigate the CVS risk.
The ongoing randomised Prostate Adenocarcinoma
[23_TD$DIFF] ransCutaneous Hormones (PATCH) (MRC PR09) trial is
assessing the safety and efficacy of transdermal oestradiol
patches ([22_TD$DIFF]OP) compared with LHRHa in the treatment of
advanced PCa (Fig. 1). The first stage (n = 254) showed that
[22_TD$DIFF]OP produced castration levels of testosterone equivalent to
LHRHa, and in addition, early CVS morbidity and mortality
was similar between the two groups [15]. A further phase of
recruitment included a confidential preplanned interim
analysis based on progression-free survival (PFS) (n = 638)that led to the extension of the trial to phase 3. This is
currently ongoing (target n = 2150), with PFS and overall
survival (OS) as coprimary outcome measures.
Here we report on a preplanned study embedded within
the PATCH trial comparing changes in BMD between the
two hormonal treatments. It was designed to evaluate the
potential benefits of transdermal oestradiol for first-line
ADT in advanced PCa and to provide support for further
evaluation of the clinical efficacy of this approach.
2. Methods
2.1. Study design and participants
Between August 2006 and September 2012,[3_TD$DIFF] men who had agreed to
enrol in the PATCH trial from seven preselected UK centres were
approached prerandomisation for enrolment into a BMD study if they
were eligible. This prospective cohort was thus a subset of the main trial
population.
The study design for the main trial was previously described
[15]. Brieﬂy,menwith locally advanced ormetastatic PCawere eligible if
[(Fig._1)TD$FIG]
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and had no history of major CVS disease. Participants were randomly
allocated to receive LHRHa or transdermal oestradiol without blinding in
a 1:2 ratio before February 2011 and then 1:1 (after recruitment was
extended following the ﬁrst stage [16]). Transdermal oestradiol was
delivered, after a dose regimen change in August 2007 [16], as four
FemSeven patches (100 mg/24 h) changed twiceweekly during the ﬁrst 4
[26_TD$DIFF]wks. This was then reduced to three patches changed twice weekly
provided testosterone levels were1.7 nmol/l. LHRHawas administered
as per local practice.
Patients were not eligible for the BMD study if[27_TD$DIFF] either: their dual-
energy x-ray absorptiometry (DXA) scans were likely to be nonevaluable
or technically difﬁcult due to [28_TD$DIFF] orthopaedic prostheses or preexisting bone
disease (degenerative joint disease, vertebral fractures, or bone
metastases in the lumbar spine [LS])[29_TD$DIFF]; or [4_TD$DIFF] they were already receiving
bone-strengthening agents or other medications (including calcium and
vitamin D) thought to affect BMD. Patients with osteoporosis (T-score:
2.5 or lower) diagnosed on the baseline scan were also excluded.
DXA scans were performed using Lunar Prodigy (General Electric,
Madison, WI, USA), Hologic Discovery, or Delphi (Hologic, Bedford, MA,
USA) machines at baseline, 1 yr, and 2 yr, with the same type of machine
used during follow-up. Assessments of BMD at the LS (L1–4), right hip,
left hip, and whole body were made. Scans were not centrally reviewed.
The protocol was approved by national regulatory and ethics
committees, and participating hospitals obtained the appropriate local
approvals. Participants provided written informed consent. The Inde-
pendent Data Monitoring Committee (IDMC) has permitted the release
of data from the BMD study while the main trial is ongoing.
2.2. Statistical analysis
The primary outcomemeasure for the BMD study was change in LS BMD
(mean L1–4) at 1 yr from baseline. Secondary outcomes were BMD
change at other sites at 1 yr and changes at all sites at 2 yr.
BMD scores were compared between randomised arms using
analysis of covariance, adjusting for baseline BMD. To account for
different types of DXA machines used, the ﬁtted models also included
machine type and an interaction between baseline BMD and machine
type, as previously done [17]. The difference between arms was
estimated from themodels based on absolute BMD score, then converted
to percentage change (for ease of clinical interpretation) by dividing by
the overall mean baseline score [18].
The target sample size was 75, allowing for 35% of patients not
having a 1-yr scan (due to illness, death, or other reason). This would
provide 80% power with a two-sided signiﬁcance level of 0.05 to detect a
difference in LS BMD change between arms, assuming the mean 1-yr
change in LS BMD was 3% in the LHRHa arm and +1% in patch arm, and
the standard deviation of the change from baseline was 6% [8,17].
The primary analysis of 1-yr LS BMD change included participants
enrolled after the patch dose regimen change [16] who had two or more
evaluable LS vertebrae within L1–4 for both baseline and 1-yr scans.
Comparison between randomised arms was based on the original
treatment allocation, ignoring subsequent changes in therapy. To
account for men allocated to OP but changed to LHRHa when disease
progressed (permitted in the protocol), sensitivity analyses were
performed including only those still on the original allocated treatment
without additional systemic anticancer therapy at their [30_TD$DIFF]1 and [31_TD$DIFF]2 yr scans;
men on OP with oestradiol levels <250 pmol/l at follow-up scans were
considered not adhering to the patch regimen and therefore excluded.
The following prespeciﬁed subgroup analyses were also performed: no
bone metastases at baseline (because PCa bone metastases are
predominantly osteoblastic and thus associated with increased BMD
[19]); men scanned using Hologic Discovery, the most commonly used
machine in the study; and for analysis of LS BMD, those with all fourL1–4 vertebrae evaluable at both baseline and follow-up scans (because
BMD varies with LS vertebrae).
Statistical analyses were performed using Stata v.13 (StataCorp,
College Station, TX, USA).
3. Results
A total of 87 patients consented to participate in the study.
Eleven were deemed ineligible after enrolment or did not
proceed (Fig. 2); six were diagnosed with osteoporosis on
the baseline scan, two had nonevaluable scans due to
extensive bone metastases, and three withdrew. Another
two were randomised before a patch dose change and so
were excluded. Baseline clinical characteristics of the
remaining 74 eligible patients were similar between the
two arms (Table 1). Median age was 77 yr (interquartile
range [IQR]: 73–80 yr), median baseline prostate-specific
antigen [32_TD$DIFF] (PSA) was 56 ng/ml (IQR: 30–112), and 43% (32 of
74) had metastatic disease.
At 3 mo, the proportion of patients with testosterone
concentrations1.7 nmol/l was 96% in both the LHRHa arm
(26 of 27) and the OP arm (42 of 44), excluding two patients
not adhering to the patch regimen (oestradiol<250 pmol/l)
and one missing testosterone value. The corresponding
proportion at 6 mo was LHRHa 85% (22 of 26) and OP 90%
(37 of 41). Median oestradiol level at 3 mo was 70 pmol/l in
the LHRHa arm (5th–95th centile range 19–114 pmol/l) and
685 pmol/ [33_TD$DIFF]l (350–1788 pmol/l) in the OP arm.
Overall, 63 patients with either 1-yr (n = 61) and/or 2-yr
(n = 48) DXA scans were included in the analyses of change
in BMD for at least one of the anatomic sites. The primary
analysis of 1-yr change in LS BMD was based on 60 men
(81% of 74 eligible patients) (Fig. 2). Three centres
(n = [34_TD$DIFF]27 participants) used [35_TD$DIFF]Hologic [36_TD$DIFF] iscovery DXAmachines,
three used [37_TD$DIFF]Lunar [38_TD$DIFF]Prodigy (n = [39_TD$DIFF]19), and one used both
Hologic Discovery (n = 11) and Hologic Delphi (n = 3). The
proportion of men scanned using Hologic Discovery, the
most commonly used machine, was 67% (14 of 21) in the
LHRHa arm and 62% (24 of 39) in the OP arm. At the 1-yr
scan, 19 of 21 LHRHa patients (90%) and 33 of 39 OP patients
(85%) were reported to still be on the original allocated
treatment only without additional anticancer therapy.
The mean 1-yr change in LS BMD was 0.021 g/cm3 [21_TD$DIFF] for
the LHRHa arm versus +0.069 g/cm3 for OP (p < 0.001). The
corresponding mean percentage changes were 1.4% and
+6.0%, respectively, with an estimated difference between
arms of 6.7% (95% confidence interval [CI], 3.7–9.7) in favour
of OP. As shown in Table 2, similar patterns with BMD
decreasing in LHRHa patients and increasing in OP patients
were seen at 1 yr for the right hip (difference between arms
+3.8% [1.4–6.2%]; p = 0.003), left hip (+4.3% [1.7–6.9%];
p = 0.002), and for whole-body measurements (+2.5% [1.0–
4.0%]; p = 0.002). Within the patch arm, there was no
evidence of an association between serum oestradiol level
and BMD change at any of the anatomic sites (data not
shown).
The differences between arms remained in all predefined
subgroup analyses, as shown in Table 3: patients still on
original allocated treatment only, no bone metastases at
[(Fig._2)TD$FIG]
5 were either ineligible, excluded, or 
had withdrawn: 
• 2 were ineligible due to osteoporosis 
diagnosed at baseline
• 1 withdrew
• 2 excluded as randomised before the 
patch dose regimen change $
8 were either ineligible, excluded, or 
had withdrawn: 
• 4 were ineligible due to osteoporosis 
diagnosed at baseline
• 2 had nonevaluable scans due to 
extensive bone metastases 
• 2 withdrew
5 patients did not have a follow-up 
DXA scan done: 
• 2 due to death 
• 1 was too ill
• 2 missed in error
6 patients did not have a follow-up 
DXA scan done: 
• 2 due to death 
• 2 were too ill
• 1 due to family circumstances
• 1 missed in error
1 patient excluded from the analysis 
of primary outcome
• Had only 1 LS vertebrae evaluable 
on both the baseline and 1-yr scans^
21 patients included in the 
analysis of 1-yr LS BMD 
change
39 patients included in the 
analysis of 1-yr LS BMD 
change
87 patients
consented to  participate in the 
BMD study
Randomised *
39 patients with 1-yr  
DXA scan
46 patients included in 
BMD study
28 patients included in 
BMD study 
22  patients with 1-yr 
DXA scan
54 in OP arm33 in LHRHa arm 
1 patient had a 2-yr but not 1-yr scan: 
needed heart surgery at the time
1 patient had a 2-yr but not 1-yr scan: 
missed in error
23 patients had follow-up DXA 
scan at 1 and/or 2 yr +
40 patients had follow-up DXA 
scan at 1 and/or 2 yr +
Fig. 2 – Flowchart of patients included in the analysis of change in lumbar spine bone mineral density at 1 yr from baseline (primary outcome
measure).
BMD = bone mineral density; DXA = dual-energy x-ray absorptiometry; LHRHa = luteinising hormone-releasing hormone [13_TD$DIFF]agonists; LS = lumbar spine;
OP = oestradiol [12_TD$DIFF]patches.
* The allocation ratio was 1:2 for LHRHa to OP before February 21, 2011, and 1:1 thereafter.
$ The patch dose regimen was increased in August 2007 [16].
+ These patients contributed to at least one of the analyses on BMD change.
^ The main analysis of the primary outcome was restricted to patients with at least two evaluable LS vertebrae within L1–4 on both the baseline and
1-yr scans.
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four L1–4 LS vertebrae evaluable at baseline and follow-up
scans.
Figure 3 shows the mean percentage BMD change over
time. As expected, the greatest absolute difference
between arms was seen at 2 yr among those still onallocated treatment only. Mean change in LS BMD was
0.047 g/cm3 (mean percentage change:3.0%) for LHRHa
and +0.088 g/cm3 (+7.9%) for OP (p < 0.001), with an
estimated difference between arms of 9.3% (95% CI,
5.3–13.4). Similar trends for absolute BMD change are
shown in Supplementary Figure 1.
Table 1 – Baseline characteristics (n = 74)*[14_TD$DIFF]
Characteristics LHRHa (n = 28) OP (n = 46)
n % n %
Age, yr
<70 4 14 9 19
70–79 15 54 24 52
80 9 32 13 28
Median (IQR) 77 (74–80) 76 (72–80)
Smoking status
Never smoked 12 43 18 39
Previous smoker 14 50 27 59
Current smoker 2 7 1 2
Metastatic disease 14 50 18 39
Bone metastases, those with metastatic disease, % 11 79 18 100
PSA, ng/ml
<50 14 50 20 43
50 to <500 14 50 23 50
500 0 0 3 7
Median (IQR) 52 (25–91) 56 (30–127)
Tumour status
T2 0 0 2 4
T3 16 57 36 78
T4 10 36 6 13
TX 2 7 2 4
Gleason score at diagnosis
4–6 4 15 7 16
7 6 22 20 44
8–10 17 63 18 40
Missing 1 – 1 –
Bone mineral density, median (IQR)
Lumbar spine BMD, g/cm3 1.335 (1.100–1.451) 1.154 (1.078–1.283)
Lumbar spine T-score 1.3 (0.1–2.6) 0.5 (0.6–1.4)
Left hip BMD, g/cm3 1.037 (0.947–1.168) 1.014 (0.921–1.075)
Left hip T-score 0.1 (0.6 to 0.8) 0.3 (0.9 to 0.1)
Right hip BMD, g/cm3 1.047 (0.982–1.162) 0.989 (0.912–1.079)
Right hip T-score 0.1 (0.6 to 0.8) 0.5 (1.0 to 0.2)
Whole-body BMD, g/cm3 1.234 (1.182–1.416) 1.232 (1.148–1.361)
Whole-body T-score 0.1 (0.3 to 2.7) 0.3 (0.8 to 1.9)
Osteopenia** 8 29 17 37
BMD = bone mineral density; IQR = interquartile range; LHRHa = luteinising hormone-releasing hormone agonists; OP = oestradiol [12_TD$DIFF]patches.
* The 60 patients included in the primary analysis of 1-yr lumbar spine BMD change had similar baseline characteristics as the overall group.
** Deﬁned as T-score greater than 2.5 and less than or equal to 1.0 at any of the sites measured (patients with osteoporosis (T-score less than or equal to 2.5)
were not eligible for the BMD study).
Table 2 – Change in bone mineral density at 1 and 2 yr from baseline
Site Arm No. of
patients
Mean absolute
change, g/cm3 [13_TD$DIFF] (SD)
Mean change,
% (SD)
Difference between
arms$ [15_TD$DIFF], % (95% CI)
p value
At 1 yr
Lumbar spine LHRHa 21 0.021 (0.057) 1.4 (4.3)
OP 39 +0.069 (0.076) +6.0 (6.1) +6.7 (3.7–9.7) <0.001
Right hip LHRHa 21 0.022 (0.033) 2.1 (3.3)
OP 37 +0.016 (0.049) +1.7 (4.8) +3.8 (1.4–6.2) 0.003
Left hip LHRHa 20 0.026 (0.016) 2.4 (1.5)
OP 34 +0.019 (0.055) +2.0 (5.5) +4.3 (1.7–6.9) 0.002
Whole body LHRHa 17 0.015 (0.043) 1.2 (3.2)
OP 35 +0.017 (0.026) +1.4 (2.1) +2.5 (1.0–4.0) 0.002
At 2 yr
Lumbar spine LHRHa 12 0.026 (0.086) 1.6 (6.4)
OP 29 +0.077 (0.060) +6.6 (5.4) +8.1 (3.8–12.4) 0.001
Right hip LHRHa 17 0.040 (0.070) 3.8 (6.8)
OP 29 +0.017 (0.044) +1.6 (4.1) +5.8 (2.3–9.3) 0.002
Left hip LHRHa 16 0.047 (0.036) 4.3 (3.3)
OP 30 +0.018 (0.031) +1.8 (3.0) +6.4 (4.3–8.5) <0.001
Whole body LHRHa 15 0.089 (0.106) 6.2 (6.7)
OP 32 +0.002 (0.069) +0.2 (5.3) +6.0 (2.0–9.9) 0.006
CI = conﬁdence interval; LHRHa = luteinising hormone-releasing hormone [13_TD$DIFF]agonists; OP = oestradiol [12_TD$DIFF]patches; SD = standard deviation[16_TD$DIFF].
$ Estimated using analysis of covariance models, as described in the Statistical analysis section.
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Table 3 – Change in bone mineral density from baseline: predefined subgroup analyses
Site Arm No. of patients Mean absolute change,
g/cm3 (SD)
Mean change,
% (SD)
Difference between arms,
% (95% CI)
p value
Patients on allocated treatment without additional anticancer therapy
At 1 yr
Lumbar spine LHRHa 19 0.021 (0.058) 1.4 (4.3)
OP 33 +0.075 (0.059) +6.5 (5.0) +6.9 (4.2–9.7) <0.001
Right hip LHRHa 18 0.030 (0.026) 2.9 (2.6)
OP 31 +0.014 (0.026) +1.4 (2.5) +4.7 (3.2–6.2) <0.001
Left hip LHRHa 17 0.026 (0.016) 2.4 (1.5)
OP 28 +0.017 (0.034) +1.7 (3.4) +4.1 (2.2–6.1) <0.001
Whole body LHRHa 14 0.019 (0.043) 1.4 (3.3)
OP 29 +0.020 (0.022) +1.6 (1.8) +2.7 (1.1–4.3) 0.002
At 2 yr
Lumbar spine LHRHa 10 0.047 (0.068) 3.0 (5.5)
OP 23 +0.088 (0.049) +7.9 (4.3) +9.3 (5.3–3.4) <0.001
Right hip LHRHa 12 0.061 (0.040) 5.8 (4.1)
OP 22 +0.022 (0.030) +2.1 (2.8) +8.6 (6.1–11.0) <0.001
Left hip LHRHa 11 0.053 (0.040) 4.9 (3.7)
OP 22 +0.019 (0.029) +1.9 (2.8) +6.6 (4.1–9.2) <0.001
Whole body LHRHa 10 0.078 (0.083) 5.6 (5.3)
OP 24 +0.005 (0.077) +0.6 (5.9) +6.5 (2.1–10.9) 0.007
Patients without bone metastases at baseline: at 1 yr
Lumbar spine LHRHa 13 0.043 (0.041) 3.2 (2.8)
OP 25 +0.065 (0.066) +5.8 (5.4) +7.9 (4.9–10.9) <0.001
Right hip LHRHa 12 0.021 (0.018) 2.0 (1.8)
OP 23 +0.009 (0.025) +0.9 (2.6) +3.2 (1.4–4.9) 0.001
Left hip LHRHa 12 0.028 (0.018) 2.7 (1.8)
OP 21 +0.014 (0.034) +1.6 (3.5) +4.0 (1.7–6.3) 0.002
Whole body LHRHa 9 0.021 (0.031) 1.7 (2.4)
OP 22 +0.019 (0.021) +1.6 (1.7) +3.0 (1.5–4.5) 0.001
Patients scanned using Hologic Discovery machines [18_TD$DIFF]: at 1 yr *[17_TD$DIFF]
Lumbar spine LHRHa 14 0.008 (0.042) 0.7 (3.8)
OP 24 +0.069 (0.069) +6.0 (5.6) +6.7 (3.5–10.0) <0.001
Right hip LHRHa 14 0.016 (0.030) 1.6 (2.9)
OP 22 +0.022 (0.059) +2.2 (5.7) +3.7 (0.3–7.0) 0.04
Left hip LHRHa 15 0.024 (0.018) 2.3 (1.7)
OP 24 +0.023 (0.060) +2.3 (5.9) +4.7 (1.5–7.9) 0.007
Whole body LHRHa 13 0.017 (0.042) 1.5 (2.9)
OP 23 +0.017 (0.024) +1.3 (1.9) +2.8 (1.2–4.5) 0.001
Patients with all four L1–L4 lumbar spine vertebrae evaluable [19_TD$DIFF]: at 1 yr **
Lumbar spine LHRHa 19 0.024 (0.049) 1.7 (3.8)
OP 28 +0.063 (0.074) +5.5 (6.0) +6.0% (2.9–9.1) <0.001
CI = conﬁdence interval; LHRHa = luteinising hormone-releasing hormone agonists; OP = oestradiol patches; SD = standard deviation.
* The most commonly used dual-energy x-ray absorptiometry machine in the study.
** On both the baseline and 1-yr scans (because bone mineral density varies with lumbar spine vertebrae).
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We report on the first randomised study to show that PCa
patients treated with transdermal oestradiol for first-line
hormonal therapy avoid the BMD loss associated with
LHRHa administration. The effect of OP on BMD preserva-
tion was seen across different anatomic sites. As expected,
the greatest absolute difference in BMD change between
treatment arms was observed at 2 yr for those receiving
only their allocated treatment for PCa during this period.
These findings are in line with the protective effect of
oestradiol on bone health among postmenopausal women
receiving oestrogen replacement therapy [20]. Our results
are supported by two previous studies of parenteral
oestradiol in PCa. First, a single-arm pilot study of
20 men treated with OP for newly diagnosed locally
advanced or metastatic disease showed BMD increased at
allmeasured sites over time [21]. Second, in the randomised
Scandinavian Prostatic Cancer Group SPCG-5 trial (n = 910)evaluating parenteral oestradiol therapy in the form of
intramuscular polyestriol phosphate (PEP), none of the
patients in the PEP arm reported serious skeletal complica-
tions compared with 18 (mainly fractures) on a combined
androgen blockade (with either LHRHa or orchidectomy)
over a median follow-up of 11 yr [22]; however, BMD was
not assessed during this study.
Our study, although relatively small, was sufficiently
powered to detect the difference between arms we were
expecting to observe, and it provided consistent evidence
for the effect of OP across all prespecified analyses. It has
certain limitations, however. First, fracture was not a
secondary outcome because of the limited sample size and
follow-up period, but data are being recorded within the
main trial. Although a strong inverse relationship between
BMD and fracture risk is known to exist, there are other
determinants of bone strength and susceptibility to
fracture [23]. Second, scans were not centrally reviewed,
although sites were requested to perform standardised DXA
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Fig. 3 – Mean percentage change (95% confidence interval) in bone mineral density at 1 and 2 yr from baseline by treatment arms. (a) All patients; (b)
patients still on allocated treatment only (ie, patients who were still on allocated treatment at the time of the scan with no additional anticancer
therapy, with those on oestradiol patch with oestradiol values <250 pmol/l assumed not to be adhering to the patch regimen). The analyses at 1 and
2 yr are based on different numbers of patients (see Tables 2 and 3).
LHRH = luteinising hormone-releasing hormone.
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DXA machine were used across sites; however[40_TD$DIFF], individual
patients were scanned with the same type of machine
during follow-up, and machine type was further accounted
for in statistical analysis.The increasing use of LHRHa in PCa management has
highlighted the need to better understand the nature and
impact of ADT. Low testosterone results in loss of libido,
erectile dysfunction, and decrease in muscle mass [24,25].
Other toxicities associated with LHRHa such as osteoporosis,
E U RO P E AN URO LOGY 6 9 ( 2 0 1 6 ) 1 0 1 6 – 1 0 2 5 1023increased fracture risk, hot flashes, and dyslipidemia are
thought to be due to oestradiol deficiency [25]. Oestradiol
deficiency prolongs the life span of bone-resorptive osteo-
clasts, with the resulting imbalance between osteoclasts and
bone-forming osteoblasts increasing the rate of bone
thinning. This heightens the risk of fracture [26,27], leading
to increased morbidity and reduced quality of life [10,28].
Potential strategies that have been suggested to mitigate
the accelerated loss of BMD with LHRHa include the
addition of calcium and vitamin D [6], bisphosphonates
[29], selective oestrogen receptor modulators [6], and
targeting the receptor activator of the nuclear factor
[41_TD$DIFF]kappa B ligand that blocks the maturation of osteoclasts
[17]. However, recent meta-analyses found that calcium
and vitamin D supplements have little impact on BMD, and
there was insufficient and inconsistent evidence of an effect
on fracture risk [30–32] [42_TD$DIFF]. Both zoledronic acid and denosu-
mab have been approved for reducing risk of skeletal-
related events (SREs) in men with castration-resistant PCa
and bone metastases. Interestingly, zoledronic acid was
shown to be effective in preventing fractures and [43_TD$DIFF]SREs [7_TD$DIFF] in a
meta-analysis of randomised trials of PCa patients by[44_TD$DIFF] Serpa
Neto et al, but not in the subsequent Cancer and Leukemia
Group B (CALGB) 90202 trial [45_TD$DIFF] which included men with
castration-sensitive PCa and bone metastases [29,33]. This
may be due to differences in patient characteristics between
studies [46_TD$DIFF]. [47_TD$DIFF] n [48_TD$DIFF]particular, within the CALGB trial, zoledronic acid
appeared to have an effect among men with an SRE before
baseline but not those without. [49_TD$DIFF] urthermore, zoledronic
acid was found to be inferior to denosumab for preventing
SREs in a randomised trial of men with [50_TD$DIFF]castration-resistant
PCa [34]. Neither denosumab or zoledronic acid, however,
was shown to improve OS [35,36]. It is worth noting, in
addition, that these various approaches involve adding
further agents to LHRHa administration and could increase
complexity for patients and health care costs. In contrast,
transdermal oestradiol as a single agent produces castration
levels of testosterone while appearing to preserve BMD.
The major concern about using oestradiol has been CVS
toxicity [12]. However, early results from the PATCH trial
[15] and previous work from Scandinavia on intramuscular
PEP [37] suggest the excess CVS mortality seen with oral
oestrogen is avoidable. In the initial cohort of 254 men in
the PATCH trial with a median follow-up of 19 mo, the
proportion of patients in the OP arm experiencing a CVS
event (10.1%; 95% CI, 6.0–15.6) was relatively similar to that
in the LHRHa arm (7.1%; 2.7–14.9), with half of the events
assigned to men on OP occurring some time after treatment
with the patches was stopped and LHRHa started. In
comparison, oral oestrogen at 5 mg/d of DES was associated
with a CVS mortality risk of 20% within the first 12 mo of
treatment [12]. CVS outcomes are closely monitored within
the ongoing PATCH trial (>900 patients recruited since
2006) and regularly reviewed bymembers of the IDMCwho,
to date, have recommended the trial continue. Another
concern with utilising oestradiol therapy is gynaecomastia,
experienced by approximately 75% of patients on patches
within the trial, although it was generally mild with 10%
having grade 3 events [15]. However, hot flashes [51_TD$DIFF], [52_TD$DIFF]which canaffect quality of life formen receiving ADT[53_TD$DIFF], are reducedwith
oestradiol therapy compared with LHRHa, and they were
reported in 25% versus 56% of patients in the two respective
arms during the first stage of PATCH [15]. Patients on OP
appeared to develop more favourable blood glucose and
lipid profiles [15].
5. Conclusions
This study identifies the first single agent that produces
castration levels of testosterone comparable with LHRHa
administration while mitigating BMD loss, thereby adding
significantly to the evidence supporting further evaluation of
parenteral oestradiol for treating PCa. The PATCH pro-
gramme, to date, has also shown that transdermal oestradiol
appears to avoid the CVS toxicity seen with oral oestrogen
and potentially results inmore favourablemetabolic profiles
than LHRHa [15]. Transdermal oestradiol may therefore be a
potentially useful and cost-effective agent for ADT in
systemic PCa, and the final results of the phase 3 trial will
provide a full assessment of efficacy and toxicity. Validation
of these BMD findings will also be required in larger cohorts.
The development of alternative approaches to ADT poten-
tially allows more personalised treatment for patients with
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